• The U.S. Justice Department has reclassified medical marijuana from Schedule I to Schedule III.
• This change allows for increased research and potential tax breaks for state-licensed medical marijuana operators.
• The reclassification follows an executive order by President Donald Trump to facilitate cannabis regulation.
• Despite the reclassification, marijuana remains illegal at the federal level.
• The rule change is expected to foster improvements in medical treatments and care for patients.

The U.S. Department of Justice has officially announced a historic reclassification of cannabis, changing its status from Schedule I narcotic to Schedule III. This adjustment places marijuana in the same category as drugs like Tylenol with codeine and aims to enhance research and access to medical treatments, as articulated by Acting Attorney General Todd Blanche. He noted, "The Department of Justice is delivering on President Trump's promise to expand Americans' access to medical treatment options," according to BBC and CBS News.

The reclassification allows the Food and Drug Administration (FDA) to approve products containing marijuana and gives state-licensed medical marijuana operators significant tax breaks and streamlined registration with the Drug Enforcement Agency (DEA). However, this move does not legalize marijuana usage under U.S. law; it merely alters how it is regulated, according to South China Morning Post and CBS News.

The decision is seen as a long-awaited improvement for many advocates who believe that marijuana should not be treated at the same level of danger as heroin. Blanche emphasized that the rescheduling action would allow for research on cannabis's safety and efficacy, ultimately providing better care for patients and more reliable information for doctors. The Trump administration's approach to accelerate this process was triggered by an executive order from December, as highlighted in reports, including BBC and South China Morning Post.

While marijuana remains illegal federally, the reclassification legitimizes medical marijuana programs in 40 states and initiates a hearing process for broader reclassification later this year, as stated by Blanche. He remarked that this decision represents a major policy shift in U.S. drug regulation, diverging from a long-standing prohibition dating back to the Marihuana Tax Act of 1937. Concerns regarding the potential for higher-strength cannabis products continue to be debated, as noted by South China Morning Post.